The company witnesses strong growth across its India, Africa, and emerging markets businesses, while securing regulatory approval for the first AB-rated gVentolin in the U.S. market
The once-weekly treatment targets Type 2 Diabetes Mellitus (T2DM) with demonstrated efficacy and safety
Profit before tax jumped 64% to Rs. 226 crore, while the company maintained robust investment in innovation with net R&D spend of Rs. 249 crore
The base Gland business posted ?11,790 million in revenue, up 16% YoY
Teva reported third quarter revenues of $4.5 billion, an increase of 3 per cent year-over-year.
Generic Saxenda is the first-ever generic GLP-1 indicated for weight loss, addressing increased demand for this category of therapies in the US market
For the full financial year FY25, revenue from operations grew 9 per cent to Rs. 11,537.8 crore, compared to Rs. 10,588 crore in FY24.
The group reported Q3FY25 operating revenue of Rs 3,821 crore, driven by sustained double-digit growth of 14 per cent in biosimilars
Revenue at Rs 3,623 crore, EBITDA at Rs 718 crore
This strong performance was primarily on account of a one-time gain from the strategic collaboration between Biocon Biologics and Eris Lifesciences.
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
